


South Sudan

African Region



I. Epidemiological profile

Population (UN Population Division)	2023	%	Parasites and vectors
High transmission (>1 case per 1000 population)	11.5M	100	Major plasmodium species (indigenous cases):
Low transmission (0-1 case per 1000 population)	-	-	<i>P. falciparum</i> : 100 (%)*, <i>P. vivax</i> : 0 (%)
Malaria free (0 cases)	-	-	Major anopheles species:
Total	11.5M	-	<i>Anopheles spp.</i> , <i>An. gambiae s.s.</i> , <i>An. arabiensis</i> , <i>An. nili</i> , <i>An. funestus s.s.</i>

*includes mixed infections and other species of Plasmodium

Reported cases and deaths		Estimates	
Presumed and confirmed cases	5 089 688	Estimated cases:	2.9M [1.9M, 4.3M]
Total confirmed cases:	3 428 237	Estimated deaths:	6.7K [3.6K, 13.7K]
Confirmed cases from public sector:	2 519 271		
Confirmed cases from private sector:	-		
Confirmed cases at community level:	908 966		
Confirmed cases in combined health sectors:	-		
Reported deaths:	1813		




II. Intervention policies and strategies

Intervention	Policies/Strategies	Yes/No	Year adopted	Antimalaria treatment policy	Medicine	Year adopted
ITN	ITNs/LLINs distributed free of charge	Yes	2008	First-line treatment of unconfirmed malaria	AS+AQ	2006
	ITN distributed by mass campaign	Yes	2008	First-line treatment of <i>P. falciparum</i>	AS+AQ	2006
IRS	IRS is recommended	Yes*	-	Second-line treatment <i>P. falciparum</i>	AL	2006
	DDT is used for IRS	No	-	Treatment of severe malaria	AS	2006
Larval control	Use of Larval Control	No	-	Treatment of <i>P. vivax</i>	PYR	2006
IPT	IPT used to prevent malaria during pregnancy	Yes	2006	Dosage of primaquine for radical treatment of <i>P. vivax</i>	0.25 mg/Kg (14 days)	
Diagnosis	Malaria diagnosis using RDT is free of charge in the public sector	Yes*	2006	Type of RDT used (public)	P.f only	
	Malaria diagnosis using microscopy is free of charge in the public sector	Yes*	2006			
	Malaria diagnosis is free in the private sector	NA	-			
Treatment	ACT is free for all ages in public sector	Yes	2006			
	The sale of oral artemisinin-based monotherapies (oAMTs)	banned	2006			
	Single low dose of primaquine (0.75 mg base/kg) with ACT to reduce transmissibility of <i>P. falciparum</i>	NA	-			
	Primaquine is used for radical treatment of <i>P. vivax</i>	NA	-			
	G6PD test is a requirement before treatment with primaquine	NA	-			
	Directly observed treatment with primaquine is undertaken	NA	-			
Surveillance	System for monitoring of adverse reaction to antimalarials exists	Disc	-			
	Malaria is a notifiable disease	Yes	2006			
	ACD for case investigation (reactive)	NA	-			
	ACD at community level of febrile cases (pro-active)	NA	-			
	Mass screening is undertaken	NA	-			
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	-			
	Uncomplicated <i>P. vivax</i> cases routinely admitted	NA	-			
	Case investigation undertaken	NA	-			
	Foci investigation undertaken	NA	-			
	Case reporting from private sector is mandatory	No	-			


Yes* = Policy adopted, but not implemented in 2023

Disc = Discontinued

Earliest year that policy is adopted was adjusted based on the earliest year that the WHO policy was recommended




Source: 2010




V.

Confirmed malaria cases per 1000 population at risk and
ABER




ABER=smears examined in a year X100 / Total population. Includes cases that are imported and introduced

Malaria inpatients and deaths




V.

Coverage of ITN and IRS




Sources of financing



VI.

Government expenditure by intervention in 2023



Footnotes
(est.) : WHO estimates based on the survey

data validated by the countries as of 14 November 2024.

Further information on the methods used to estimate malaria cases and an explanation for the gap between estimated and reported confirmed indigenous cases is provided [mpac-april2018-erg-report-malaria-burden-session6.pdf \(who.int\)](#)

World Malaria Report 2024